DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.
News & Analysis: Novo Nordisk
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.
Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.
Traders cheered the company's first quarter earnings report.
Shares tumbled after management poured cold water on the company's long-term growth targets.
The diabetes specialist cuts short- and long-term growth outlooks.
A management shake-up and staff cutbacks reignited fears of declining U.S. sales ahead.
Increasing pricing pressure for diabetes treatments in the U.S. continue to plague the Danish pharma.
Pricing pressure has investors worried about the pharma's future drug sales.